InMode Limited, which develops and markets minimally-invasive medical aesthetic products, filed on Thursday with the SEC to raise up to $75 million in an initial public offering.
The Yokneam, Israel-based company was founded in 2008 and booked $110 million in sales for the 12 months ended March 31, 2019. The company changed its name from Invasix to InMode in November 2017. It plans to list on the Nasdaq under the symbol INMD. Barclays and UBS Investment Bank are the joint bookrunners on the deal. No pricing terms were disclosed.
